The cellular hypersensitivity to the PARP inhibitor Olaparib and the chromosomal hypersensitivity to MMC clearly support a significant loss of the DNA repair capability of BRCA1 in the patient and are compatible with a diagnosis of FA [11,12,13]. This evidence concerns the gene BRCA1 and Friedreich ataxia.